[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular director John A. Roush received multiple dividend equivalent rights tied to prior equity awards that vest proportionately with those awards. The Form 4 reports acquisitions on 09/04/2025 of dividend equivalent rights that are the economic equivalent of common stock: 0.4173, 0.4173, 0.7138, 0.8546 and 0.8697 shares, each recorded as acquired at $0 price and held directly. Each set of rights accrued on RSU or PSU awards granted in 2022, 2023 and 2024 and will vest in line with those underlying awards, converting economically into common stock when vested.

Positive

• Clear disclosure of dividend equivalent rights accrued on prior RSU and PSU awards, including grant years and vesting linkage
• Direct beneficial ownership recorded with zero cash consideration, indicating non-cash administrative accruals rather than market transactions

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine accrual of dividend equivalents on existing equity awards; immaterial to near-term valuation.

The filing documents small fractional dividend equivalent rights accrued on previously granted RSUs and PSUs and recorded as direct beneficial ownership. The amounts per line (0.4173, 0.4173, 0.7138, 0.8546, 0.8697) are fractional and arose from awards granted in 2022, 2023 and 2024. There is no cash consideration and no new option exercises or stock sales reported. For investors, this is a standard administrative update reflecting non-cash accruals rather than a material change in insider position.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting for equity-based compensation; no governance concerns noted.

The reporting person is identified as a director and the Form 4 discloses dividend equivalent rights tied to RSU and PSU awards that vest proportionately. Each accrual is described as the economic equivalent of one share and recorded as direct ownership. The explanation references grant dates for the underlying awards and clarifies vesting linkage, meeting transparency expectations for insider compensation reporting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roush John A

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, 63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		0.4173		(1)	(1)	Common Stock	0.4173	$0	6.5156	D
Dividend Equivalent Rights	(2)	09/04/2025		A		0.4173		(2)	(2)	Common Stock	0.4173	$0	5.5269	D
Dividend Equivalent Rights	(3)	09/04/2025		A		0.7138		(3)	(3)	Common Stock	0.7138	$0	5.3975	D
Dividend Equivalent Rights	(4)	09/04/2025		A		0.8546		(4)	(4)	Common Stock	0.8546	$0	5.8691	D
Dividend Equivalent Rights	(5)	09/04/2025		A		0.8697		(5)	(5)	Common Stock	0.8697	$0	2.9094	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did John A. Roush report on the Form 4 for LMAT?

The Form 4 reports acquisitions of several dividend equivalent rights tied to prior RSU and PSU awards, recorded as direct beneficial ownership.

How many dividend equivalent rights were acquired and at what price?

The filing lists acquisitions of 0.4173, 0.4173, 0.7138, 0.8546, and 0.8697 dividend equivalent rights, each recorded at $0 price.

Are the dividend equivalent rights linked to specific grant dates?

Yes. The rights accrued on awards granted on 12/12/2022, 12/8/2023, and 12/6/2024 and vest proportionately with those awards.

Do these entries reflect stock purchases or option exercises?

No. They reflect accrued dividend equivalent rights (non-cash) associated with existing equity awards, not purchases or exercises.

Does the Form 4 indicate any change in control or large insider sale?

No. The filing shows only accruals of dividend equivalent rights and does not disclose any sales, transfers, or control changes.